[작성자:] cms3billion

3billion people participated in ESHG 2023, held in Glasgow, Scotland, UK, from June 10th to 13th. This year, we operated a booth, held a Corporate Satellite event, and presented a poster on the topic of “Diagnostic Performance of Exome Sequencing on 18,995 Patients with Suspected Rare Genetic Disorders” after participating in the event for the…

On 8th December, Dr. Hane Lee, Chief Genomics Officer at 3billion, lectured on ‘Application of NGS-based Genetic Testing in Diagnosing Rare Mendelian Disorders’ at the University of Patras postgraduate program. The guest lecture was hosted by the Institute of Precision Medicine of the University of Patras, in collaboration with the postgraduate program Personalized Medicine, Life Sciences Informatics and Biomedical Sciences…

We are pleased to announce that our website has undergone a major renewal and is now online! What changed? We will continue to develop our website to make genetic testing simple. Please do not hesitate to share your experience – both good and bad – through the feedback form. Thank you for visiting our website!

Diagnostic performance of automated, streamlined, daily updated exome analysis in patients with neurodevelopmental delay 3billion announced that Chief Medical Officer Dr. Gohun Seo will be introducing a poster at ACMG 2022. This poster highlights the importance of continuous reanalysis for undiagnosed patients. In a previous single-center pilot study, Dr. Seo introduced a new automated, streamlined…

The Korean startup, having only been founded in October 2016, is already on track to go public in early 2022 on the KOSDAQ. The KOSDAQ and the South Korean government have prioritized and created a fast-track process for technology companies to go public for several years now. CEO Changwon Keum noted that the KOSDAQ has…

A research paper on 3billion’s automated variant prioritization system, EVIDENCE, published in Wiley’s Clinical Genetics Journal in December 2020, was selected as the ‘Top Cited Article’ during 2020-2021. This announcement made it clear that the industry is paying attention to automated variant analysis technology of 3billion. 3billion recognized that the existing manual variant prioritization method was time-consuming and…

3billion plans to form a consortium with Seoul National University Hospital and Kakao Healthcare to develop an AI integrated software solution for multifaceted analysis of rare diseases in nine groups for three years from 2022 to 2024. 3billion will be in charge of developing WGS (Whole Genome Sequencing)-based diagnostic AI models and SW solutions. The…

Let’s take a look at the interview article with ‘Korea Biomedical Review’ of 3billion’s CEO Changwon Keum. There are many difficulties in diagnosing rare genetic disorders as well as finding cures. Each patient has an average of 100,000 genetic variants, and it is not easy to determine one pathogenic variant that causes a rare genetic…

3billion has received CAP accreditation on November 15th. CAP accreditation is an evaluation system by the College of American Pathologists, an organization of clinical pathologists in the United States. This accreditation officially signifies that the quality of our rare disease diagnostic services meets global standards. 3billion currently provides services to more than 200 institutions in…

SEOUL, SOUTH KOREA—3billion has announced 3Cnet, a pathogenicity prediction tool based on recurrent neural networks (RNN). 3Cnet boasts a top-1 recall of 14.5%–approximately 2.2 times greater than REVEL’s leading top-1 recall of 6.5%–when used to retrieve pathogenic variants in 111 patient cases diagnosed according to the ACMG guidelines, respectively. 3Cnet’s fundamental approach utilizes protein sequences…